Ocugen Inc
NASDAQ:OCGN

Watchlist Manager
Ocugen Inc Logo
Ocugen Inc
NASDAQ:OCGN
Watchlist
Price: 1.67 USD -1.18% Market Closed
Market Cap: 521.6m USD

Operating Margin

-1 112.9%
Current
Declining
by 99.4%
vs 3-y average of -1 013.4%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-1 112.9%
=
Operating Income
$-59.8m
/
Revenue
$5.4m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-1 112.9%
=
Operating Income
$-59.8m
/
Revenue
$5.4m

Peer Comparison

Country Company Market Cap Operating
Margin
US
Ocugen Inc
NASDAQ:OCGN
521.6m USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
378.3B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
178.1B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
154.2B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
112.3B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.3B USD
Loading...
AU
CSL Ltd
ASX:CSL
85.3B AUD
Loading...
NL
argenx SE
XBRU:ARGX
41.9B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
46.9B USD
Loading...
No Stocks Found

Market Distribution

Lower than 94% of companies in the United States of America
Percentile
6th
Based on 14 112 companies
6th percentile
-1 112.9%
Low
-4 087 900% — -5.1%
Typical Range
-5.1% — 14.8%
High
14.8% — 1 032 600%
Distribution Statistics
the United States of America
Min -4 087 900%
30th Percentile -5.1%
Median 6%
70th Percentile 14.8%
Max 1 032 600%

Ocugen Inc
Glance View

Market Cap
521.6m USD
Industry
Biotechnology

Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. The company is headquartered in Malvern, Pennsylvania and currently employs 56 full-time employees. The company went IPO on 2014-12-03. The firm's technology pipeline includes: COVID-19 Vaccine (0.5), Modifier Gene Therapy Platform and Novel Biologic Therapies for Retinal Diseases. COVID-19 Vaccine candidate is focused on developing, manufacturing and commercializing COVAXIN for the prevention of COVID-19 in humans in the Ocugen Covaxin Territory. COVAXIN is a whole-virion inactivated COVID-19 vaccine candidate and is formulated with the inactivated SARS-CoV-2 virus. The Modifier Gene Therapy platform is designed for retinal diseases, including retinitis pigmentosa (RP), leber congenital amaurosis (LCA) and dry age-related macular degeneration (AMD). The company is developing OCU200, a biologic product candidate to treat diabetic macular edema (DME), diabetic retinopathy (DR) and wet AMD. OCU400, its first product candidate being developed with its modifier gene therapy platform.

OCGN Intrinsic Value
3.08 USD
Undervaluation 46%
Intrinsic Value
Price
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-1 112.9%
=
Operating Income
$-59.8m
/
Revenue
$5.4m
What is Ocugen Inc's current Operating Margin?

The current Operating Margin for Ocugen Inc is -1 112.9%, which is below its 3-year median of -1 013.4%.

How has Operating Margin changed over time?

Over the last 2 years, Ocugen Inc’s Operating Margin has decreased from -1 085.7% to -1 112.9%. During this period, it reached a low of -1 350.4% on Dec 31, 2024 and a high of -597.2% on Sep 30, 2024.

Back to Top